Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 189

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 189
---
 board of directors, and Pini Ben Elazar, a director nominee. The Bridge Loans
shall bear interest at 8% per annum until maturity and we agreed to pay the lenders an additional risk premium equal to 30% of their respective
loan amount. In October 2024, we amended the Bridge Loans pursuant to which the Bridge Loans may be extended beyond March 31, 2025 and
until June 30, 2025, subject to the Registration Statement effectiveness not later than March 31, 2025 and the fulfillment of additional
cumulative conditions. Furthermore, upon the occurrence of a Qualifying IPO, the Bridge Loan lenders, shall be granted warrants to purchase
such number of Ordinary Shares equal to two times their respective loan amount in addition to the risk premium based on a price per share
equal to 75% of the lowest price per share of the Company’ Ordinary Shares during the first five trading days following the consummation
of such initial public offering. The chairman of our board of directors is a lender under one of the Bridge Loans. As of March 3,
2025, the Company received $350,000 under such Bridge Loans.

Between December 2023 and January 2024, we entered into loan agreements,
or the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate amount of $150,000 from the lenders thereto including
certain related parties including Dr. Ehud Geller, the chairman and a member of our board of directors and SCP Vitalife Partners (which
is affiliated with our director, Jeff Dykan). In October 2024, we amended the 2024 Loan Agreements pursuant to which the 2024 Loan Agreements
have been extended until August 31, 2025, shall bear interest at 8% per annum until maturity commencing as of September 1, 2024 and we
agreed to pay the lenders at maturity an additional aggregate amount of $45,000 as a risk premium. Furthermore, upon the occurrence of
a Qualifying IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two
times their respective loan amount in addition to a risk premium based on a price per share equal to 75% of the lowest price per share
of the Company’ Ordinary Shares during the first five trading days following the consummation of such initial public offering.

On December 1, 2024, we entered